Haemonetics (NYSE:HAE) announced today that it has completed its previously announced sale of its whole blood assets to GVS S.p.A. The sale has a total cash consideration of up to $67.8 million, including $45.3 million upfront after giving effect to certain customary adjustments. The deal also includes $22.5 million in contingent earn-outs over the next […]
Haemonetics
A Haemonetics EVP is retiring
Haemonetics (NYSE:HAE) announced today that Josep Llorens, EVP of global manufacturing and supply chain, plans to retire. Llorens intends to retire from the company, effective July 11, 2025. He plans to remain in his current role while the company conducts a search for his successor, assisting Haemonetics President and CEO Chris Simon in the transition […]
Haemonetics sells off whole blood assets for $67.1M
Haemonetics (NYSE:HAE) announced today that it agreed to sell its whole blood assets to GVS S.p.A for $67.1 million. GVS, a manufacturer of filter solutions for healthcare and life sciences, agreed to pay $44.6 million up front. The deal also includes up to $22.5 million in contingent earn-outs over the next four years. Under the […]
Haemonetics to lay off 75 in California facility closure
Haemonetics (NYSE:HAE) recently filed with the state of California to confirm a facility closure that affects a total of 75 employees. According to the California Worker Adjustment and Retraining Notification program, the medtech company notified the state on Oct. 22 and the state processed the filing on Nov. 6. It outlines the permanent closure of […]
Haemonetics kicks off full market launch of venous closure device
Haemonetics today announced the full market release of its Vascade MVP XL mid-bore venous closure system. The company made Vascade MVP XL fully available to U.S. hospitals as an option to promote rapid hemostasis. Haemonetics began the initial rollout for the system, which holds FDA premarket approval, in June. That limited launch reached about 80 […]
Haemonetics launches new Vascade MVP XL mid-bore venous closure device
Haemonetics (NYSE:HAE) this week announced a limited market release of its new Vascade MVP XL mid-bore venous closure device. The device expands Haemonetics’ Vascade portfolio of vascular closure systems with collapsible disc technology and resorbable collagen patches. Vascade MVP XL has FDA premarket approval. The company said the Vascade systems can save time for hospital staff […]
Haemonetics announces $525M offering
Haemonetics announced its intention to offer $525 million in convertible senior notes due 2029 in a private offering. The Boston-based company’s notes accrue interest payable semi-annually in arrears. They mature on June 1, 2029, unless earlier repurchased, redeemed or converted. Haemonetics also expects to grant initial purchasers of the notes an option to purchase up […]
Haemonetics wins FDA clearance for hemostasis cartridge
Haemonetics announced today that it received FDA 510(k) clearance for its TEG 6s hemostasis analyzer system assay cartridge. The new cartridge extends Haemonetics’ TEG 6s viscoelastic testing capabilities. It can now serve fully heparinized patients in adult cardiovascular surgeries/procedures and liver transplantation in both laboratory and point-of-care settings. Dr. Jan Hartmann, SVP and chief medical […]
Haemonetics completes Attune Medical acquisition
Haemonetics announced today that it completed its previously announced acquisition of Attune Medical. Boston-based Haemonetics agreed to buy Attune for an upfront cash payment of $160 million just under a month ago. Chicago-based Attune medical develops the ensoETM proactive esophageal cooling device. The company designed ensoETM to reduce the likelihood of ablation-related esophageal injury. These […]
Haemonetics agrees to acquire esophagus-protecting device maker Attune Medical
Haemonetics announced today that it entered into an agreement to acquire Attune Medical. Boston-based Haemonetics agreed to buy Attune for an upfront cash payment of $160 million. The deal also includes additional contingent consideration based on sales growth in the three years following the consummation of the acquisition. These additional payments also hinge on other […]
Haemonetics completes $255M OpSens acquisition
Haemonetics announced today that it completed its previously announced acquisition of cardiology-focused medical device company OpSens. Boston-based Haemonetics first announced plans to buy OpSens for more than $250 million in October. Upon completion of the deal, the company acquired all outstanding shares at a fully diluted equity value of about $255 million. As a result, […]
